Alnylam Pharmaceuticals
ALNY
#1119
Rank
A$30.33 B
Marketcap
A$226.49
Share price
0.43%
Change (1 day)
-66.68%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): A-$6.04

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$28.65. In 2022 the company made an earnings per share (EPS) of A-$13.44 a decrease over its 2021 EPS that were of A-$10.41.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)A-$6.04-55.05%
2022A-$13.4429.03%
2021A-$10.41-3.36%
2020A-$10.77-8.48%
2019A-$11.777.67%
2018A-$10.9339.74%
2017A-$7.8212.94%
2016A-$6.9338.84%
2015A-$4.99-32.88%
2014A-$7.43259.44%
2013A-$2.07-31.25%
2012A-$3.0152.94%
2011A-$1.9730.77%
2010A-$1.50-8.77%
2009A-$1.6578.12%
2008A-$0.93-70.78%
2007A-$3.1799.09%
2006A-$1.59-43.88%
2005A-$2.83-82.33%
2004A-$16.04-59.23%
2003A-$39.35

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$7.59-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$2.75-90.39%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$60.61 111.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$3.80-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.06-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.13-100.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$0.91-96.82%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A-$4.82-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA